HealthEquity, Inc. (NASDAQ:HQY - Free Report) - Equities researchers at Zacks Research upped their FY2025 earnings per share (EPS) estimates for shares of HealthEquity in a report issued on Monday, December 30th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $2.30 per share for the year, up from their previous forecast of $2.25. The consensus estimate for HealthEquity's current full-year earnings is $3.12 per share.
Several other research firms have also weighed in on HQY. Mizuho began coverage on shares of HealthEquity in a report on Wednesday, December 4th. They set an "outperform" rating and a $126.00 price objective for the company. Royal Bank of Canada boosted their price objective on HealthEquity from $100.00 to $105.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 10th. JMP Securities lifted their price target on HealthEquity from $105.00 to $107.00 and gave the company a "market outperform" rating in a report on Tuesday, December 10th. Barrington Research increased their price objective on shares of HealthEquity from $105.00 to $120.00 and gave the stock an "outperform" rating in a report on Monday, December 2nd. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of HealthEquity from $102.00 to $103.00 and gave the stock a "buy" rating in a research note on Wednesday, September 4th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $110.71.
Check Out Our Latest Stock Analysis on HQY
Shares of HealthEquity stock opened at $95.95 on Wednesday. HealthEquity has a 52-week low of $65.01 and a 52-week high of $105.82. The firm has a market capitalization of $8.32 billion, a PE ratio of 88.03, a price-to-earnings-growth ratio of 1.08 and a beta of 0.55. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.20 and a quick ratio of 4.10. The company's fifty day moving average price is $96.34 and its two-hundred day moving average price is $85.22.
In related news, Director Frank Corvino sold 1,039 shares of the business's stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total transaction of $99,847.90. Following the transaction, the director now directly owns 3,784 shares of the company's stock, valued at approximately $363,642.40. The trade was a 21.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stuart B. Parker sold 25,000 shares of the firm's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $96.72, for a total value of $2,418,000.00. Following the sale, the director now directly owns 19,061 shares of the company's stock, valued at $1,843,579.92. This represents a 56.74 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,539 shares of company stock valued at $4,040,303 in the last 90 days. 2.20% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in HQY. International Assets Investment Management LLC acquired a new stake in HealthEquity during the second quarter worth approximately $35,000. Paladin Wealth LLC bought a new position in HealthEquity in the third quarter valued at approximately $39,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in HealthEquity during the second quarter worth $73,000. GAMMA Investing LLC raised its holdings in shares of HealthEquity by 57.8% during the 3rd quarter. GAMMA Investing LLC now owns 939 shares of the company's stock worth $77,000 after buying an additional 344 shares in the last quarter. Finally, Quarry LP boosted its stake in HealthEquity by 418.8% in the third quarter. Quarry LP now owns 1,349 shares of the company's stock valued at $110,000 after buying an additional 1,089 shares in the last quarter. Institutional investors own 99.55% of the company's stock.
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.